| Autor: |
Eran Kalmanovich, Pascal Battistella, Philippe Rouviere, Bernard Albat, Jean-Marc Frapier, Roland Demaria, Fabien Huet, Audrey Agullo, Marc Mourad, Pascal Colson, Florence Leclercq, Philippe Gaudard, François Roubille |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Future Science OA, Vol 7, Iss 4 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2056-5623 |
| DOI: |
10.2144/fsoa-2020-0186 |
| Popis: |
Background: Novel oral anticoagulants are used in atrial fibrillation. Idarucizumab has been approved for reversal of dabigatran in situations of life-threatening hemorrhage or emergency surgery. Objectives: We report a single center experience of ten patients on dabigatran therapy who were given idarucizumab prior to heart transplantation. Methods & results: The mean plasma concentration of dabigatran prior to reversal was 139 ± 89 ng/ml. Hemoglobin, hematocrit and platelet levels were decreased after surgery. Surgical procedures were successfully performed with no increased risk, especially regarding bleeding complications. All patients were alive after 90 days. Conclusion: Dabigatran reversal with idarucizumab in contexts of emergency surgery/urgent procedures is an attractive and safe option to be taken into consideration for patients with end stage heart disease awaiting transplantation and indication of anticoagulant therapy. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
